(AGENPARL) – NEW HAVEN, CONNECTICUT (USA) ven 14 aprile 2023 A new Yale-led clinical trial found that the JAK inhibitor ritlecitinib may be safe for treating adolescents with the skin disease alopecia areata.
Fonte/Source: https://news.yale.edu/2023/04/13/testing-new-treatment-alopecia-areata-safe-adolescents